ACRX - AcelRx Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
175.55M
Enterprise Value 3
111.19M
Trailing P/E
N/A
Forward P/E 1
-3.16
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
79.94
Price/Book (mrq)
N/A
Enterprise Value/Revenue 3
50.63
Enterprise Value/EBITDA 6
-2.47

Trading Information

Stock Price History

Beta (3Y Monthly) 1.92
52-Week Change 3-47.23%
S&P500 52-Week Change 39.32%
52 Week High 35.0500
52 Week Low 31.9900
50-Day Moving Average 32.3094
200-Day Moving Average 32.6372

Share Statistics

Avg Vol (3 month) 3784.13k
Avg Vol (10 day) 3333.87k
Shares Outstanding 579.44M
Float 78.36M
% Held by Insiders 111.62%
% Held by Institutions 119.73%
Shares Short (Sep 30, 2019) 413.47M
Short Ratio (Sep 30, 2019) 416.91
Short % of Float (Sep 30, 2019) 417.35%
Short % of Shares Outstanding (Sep 30, 2019) 416.96%
Shares Short (prior month Aug 30, 2019) 414.09M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-2,093.99%

Management Effectiveness

Return on Assets (ttm)-31.98%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)2.2M
Revenue Per Share (ttm)0.03
Quarterly Revenue Growth (yoy)15.00%
Gross Profit (ttm)-14.96M
EBITDA -44.97M
Net Income Avi to Common (ttm)-51.1M
Diluted EPS (ttm)-0.7110
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)91.55M
Total Cash Per Share (mrq)1.15
Total Debt (mrq)28.77M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)11.69
Book Value Per Share (mrq)-0.23

Cash Flow Statement

Operating Cash Flow (ttm)-40.85M
Levered Free Cash Flow (ttm)-28.81M